Alzheimer’s disease (AD): investigations
Evidence-based neurology checklist on alzheimer’s disease (ad): investigations: Blood tests Vitamin B12 Folate Glucose Calcium Full blood count Liver function tests Renal function tests Thyroid function tests Syphilis screening Lyme serology HIV screening Consider genetics Magnetic resonance…
Blood tests
- Vitamin B12
- Folate
- Glucose
- Calcium
- Full blood count
- Liver function tests
- Renal function tests
- Thyroid function tests
- Syphilis screening
- Lyme serology
- HIV screening
- Consider genetics
Magnetic resonance imaging (MRI): features
Amyloid positron emission tomography (amyloid PET)
TAU positron emission tomography (Tau PET)
Other imaging
Cerebrospinal fluid (CSF) analysis
Neurophysiology
References
- Hort J, O’Brien JT, Gianotti G, et al. EFNS guidelines for the diagnosis and management of Alzheimer’s disease. Eur J Neurol 2010; 17:1236-1248.
- Inoue Y, Nakajima M, Uetani H, et al. Diagnostic significance of cortical superficial siderosis for Alzheimer disease in patients with cognitive impairment. Am J Neuroradiol 2016; 37:223-227.
- Lorenzi RM, Palesi F, Castellazzi G, et al. Unsuspected involvement of spinal cord in alzheimer disease. Front Cell Neurosci 2020; 14:6.
- Bakkour A, Morris JC, Dickerson BC. The cortical signature of prodromal AD: regional thinning predicts mild AD dementia. Neurology 2009; 72:1048–1055.
- Weston PS, Nicholas JM, Lehmann M, et al. Presymptomatic cortical thinning in familial Alzheimer disease: a longitudinal MRI study. Neurology 2016; 87:2050-2057.
- And 6 more. Subscribe to see the full list
Related checklists
- Alzheimer’s disease (AD): risk factors
- Alzheimer’s disease (AD): protective factors
- Alzheimer’s disease (AD): clinical features
- Alzheimer's Disease (AD) v frontotemporal dementia (FTD)
- Alzheimer’s disease (AD): emerging investigations
- Alzheimer’s disease (AD): preventative measures
- Alzheimer’s disease (AD): non-drug management
- Alzheimer’s disease (AD): conventional drug treatments
- Alzheimer’s disease (AD): lecanemab treatment
- Alzheimer’s disease (AD): investigational treatments
- Alzheimer’s disease: driving and safety issues